Brugada syndrome flecainide

Priori SG, Napolitano C, Schwartz PJ, Bloise R, Crotti L, Ronchetti E. The elusive link betw een LQT3 and Brugada syndrome the role of flecainide challenge. Circulation 2000 102(9) 945-7. 

Note LQTS can be provoked by potassium channel blockers (e.g., quinidine, sotalol), and Brugada syndrome can be provoked by potent sodium channel blockers (e.g., cocaine, flecainide). LQTS3 and Brugada may coexist. 

Cardiovascular Flecainide is used diagnostically to uncover latent Brugada syndrome in patients with the SCN5A mutation. However, sporadically it can accidentally reveal a Brugada pattern when used for therapeutic purposes in other dysrhythmias, and caution is recommended when selecting it for their treatment. 

Cardiovascular An overdose of flecainide may manifest as prolongation of the PR, QRS, and QTc intervals on ECG and the development of bradycardia, premature ventricular complex (PVC), ventricular tachycardia, and fibrillation. The ECG changes observed in flecainide toxicity may resemble Brugada syndrome [24]. 

---